|
|
||||
![]() |
Friday Jul 04
|
|||
| |
||||
Healthcare
A Cubist Masterstroke
Bayside boat-themed beds recalled
by Brian Lawler - July 4, 2008 - 0 comments
Once a pharma gets its first drug approved, one of the hardest things to do is to capture the spoils. It's easy to burn through boatloads of cash to market the drug, or to get cornered into a marginal commercialization deal and settle on getting royalties from a large-cap pharmaceutical marketing partner.
by MT Bureau - July 4, 2008 - 0 comments
Washington -- The U.S. Consumer Product Safety Commission announced a voluntary recall of Bayside Furnishing's boat-themed beds after the strangulation death of a toddler. by MT Bureau - July 4, 2008 - 0 comments
washington -- The U.S. Consumer Product Safety Commission announced a voluntary recall of Bead Bazaar USA children's jewelry due to lead exposure. by MT Bureau - July 3, 2008 - 0 comments
Washington -- The U.S. Food and Drug Administration announced the nationwide recall of "Rize 2 The Occasion" and "Rose 4 Her" sexual supplements due to a health hazard. by MT Bureau - July 3, 2008 - 0 comments
Lausanne, Switzerland -- Swiss scientists announced an achievement in supercomputing simulations they say could vastly improve osteoporosis diagnosis and treatment. by Brian Orelli - July 2, 2008 - 0 comments
Normally, issuing final approvals for Abbreviated New Drug Applications (ANDAs) at the FDA is just another day on the job. But the ANDA granted to Teva Pharmaceuticals (Nasdaq: TEVA) yesterday for its generic version of Johnson & Johnson 's (NYSE: JNJ) Risperdal must have stung just a little.
by Brian Lawler - July 2, 2008 - 0 comments
FDA-caused drug approval delays are never something for a drugmaker to be overjoyed about, but at least GlaxoSmithKline 's (NYSE: GSK) investors have a better idea of how long the wait will be. On Monday, the drugmaker announced that a vaccine highly important to its future likely won't need new clinical studies before it gets approved.
by Selena Maranjian - July 2, 2008 - 0 comments
I admit it: I'm no sports nut. Still, I find an occasional game fun to watch, and I recently read a review of the Michael Lewis book Moneyball, which tells the story of how the Oakland A's grew so successful.
by Brian Orelli - July 1, 2008 - 0 comments
Merck (NYSE: MRK) and Schering-Plough (NYSE: SGP) are ending their joint venture.
by Rich Smith - July 1, 2008 - 0 comments
Riddle me this. If your business aims to develop new "value-added services for ... desktop products and innovative online offerings ... [focusing] on both traditional and new markets across the globe, while embracing social networking and mobile technology trends," what's your first step to reach that goal?
by MT Bureau - July 1, 2008 - 0 comments
Washington -- The U.S. Consumer Product Safety Commission announced a voluntary recall of two models of Hewlett-Packard fax machines due to a fire hazard. by Brian Orelli - July 1, 2008 - 0 comments
Merck (NYSE: MRK) has given investors a lot of headaches lately. From Merck's and Schering-Plough 's (NYSE: SGP) problems with Vytorin and Zetia to its own issues with the drug formally known as Cordaptive, Merck's investors have had good reason to push the stock down 35% since the beginning of the year.
by Nisha Bhatia - July 1, 2008 - 0 comments
Good news! Good news for those who want go in for TB tests but are apprehensive and suspicious about the currently used lengthy method of testing. by MT Bureau - June 30, 2008 - 0 comments
Indianapolis -- Cymbalta has been racking up U.S. government approvals for a variety of uses since it was introduced as an anti-depressant in 2004, healthcare analysts say. by Brian Lawler - June 28, 2008 - 0 comments
The money from CV Therapeutics ' (Nasdaq: CVTX) recently approved medical diagnostic compound Lexiscan keeps rolling in. On Tuesday, CVT announced that it had received a $10 million milestone payment as a result of the marketing launch of the drug.
|
|
||||||
Disclaimer: The views and investment tips expressed by investment experts on themoneytimes.com are their own, and not that of the website or its management. TheMoneyTimes advises users to check with certified experts before taking any investment decision. ©2004-2008 All Rights Reserved unless mentioned otherwise. [Submit News/Press Release][Terms of Service] [Privacy Policy] [About us] [Contact us] |